Topic: multiple sclerosis
Now that ozanimod has finally reached the finish line, it will face a range of challenges, starting with a delayed launch due to COVID-19.
Amid federal kickback charges, Novartis escaped a yearslong whistleblower lawsuit alleging it paid doctors to boost scripts of MS blockbuster Gilenya.
Merck KGaA's aging multiple sclerosis med Rebif has caught the eye of French researchers as a possible treatment for COVID-19.
Competing with multiple blockbusters in multiple sclerosis, Merck KGaA's Mavenclad is making a name for itself with skyrocketing sales.
11 would-be blockbusters span several therapeutic areas, including CNS, oncology, hematology, inflammatory diseases and metabolic disorders.
Biogen investors have been on a wild ride in recent months, and on Wednesday they experienced their first major jolt in 2020.
Despite recent launches of rival MS drugs, Biogen is maintaining its market share, even as it spends big to prep for an expected Alzheimer's debut.
Roche Pharmaceuticals chief Bill Anderson played down gene therapy's near-term threat to Hemlibra, arguing hemophilia A patients are "well-served."
Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.